Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | 4,381.74% | 1,766.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | 4,381.74% | 1,766.46% |
| Cost of Revenue | -92.08% | -107.74% | -51.02% | -35.41% | -83.74% |
| Gross Profit | -101.00% | -98.65% | 1,434.47% | 1,197.09% | 239.40% |
| SG&A Expenses | 46.77% | -26.65% | 37.16% | -10.87% | -41.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 68.83% | -121.65% | -109.28% | -35,540.00% | -- |
| Total Operating Expenses | -4.04% | -30.07% | -0.20% | -16.89% | -26.25% |
| Operating Income | -27.77% | 13.44% | 21.98% | 35.99% | 44.06% |
| Income Before Tax | -8.83% | -29.47% | -6.46% | 10.89% | 19.99% |
| Income Tax Expenses | -297.73% | 86.74% | 96.80% | 98.88% | 98.57% |
| Earnings from Continuing Operations | -8.62% | -31.21% | -8.83% | 7.67% | 16.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -72.48% | 23.64% | 0.00% | 0.00% | 9.00% |
| Net Income | -8.77% | -31.22% | -8.84% | 7.68% | 16.73% |
| EBIT | -27.77% | 13.44% | 21.98% | 35.99% | 44.06% |
| EBITDA | -28.89% | 14.94% | 24.56% | 38.20% | 45.79% |
| EPS Basic | -5.86% | -26.50% | -5.00% | 10.56% | 18.88% |
| Normalized Basic EPS | -27.51% | 15.74% | 25.52% | 38.66% | 45.85% |
| EPS Diluted | -5.79% | -26.19% | -4.91% | 10.60% | 19.01% |
| Normalized Diluted EPS | -27.51% | 15.74% | 25.52% | 38.66% | 45.85% |
| Average Basic Shares Outstanding | 3.00% | 3.60% | 3.39% | 2.97% | 2.51% |
| Average Diluted Shares Outstanding | 3.00% | 3.60% | 3.39% | 2.97% | 2.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |